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Introduction 
Adverse reactions to pharmaceutical and diagnostic 
products constitute a major hazard in the practice of 
medicine and are responsible for substantial 
morbidity and cost. Adverse drug reactions can be 
divided into predictable and unpredictable 
reactions. Predictable reactions including drug 
toxicity, drug interactions, and adverse effects are 
dose dependent, can be related to known 
pharmacologic actions of the drug and occur in 
patients without any unique susceptibility. In 
contrast, unpredictable reactions are dose 
independent, often not related to the pharmacologic 
actions of the drug and occur in susceptible 
patients. These include idiosyncratic reactions, 
allergic (hypersensitivity) reactions, and 
pseudoallergic reactions. Pseudoallergic reactions 
resemble allergic reactions but are distinguished by 
the fact that an immunologic mechanism is not 
involved.1 In this review, we will concentrate on 
drug allergy, its underlying immunological 
abnormalities, clinical manifestations, diagnosis 
and management.  
 
Definition and Epidemiology: 
Definition: Drug allergy is an unpredictable 
immunologically mediated response to a 
pharmaceutical and/or formulation (excipient) agent 
in a sensitized person with heterogeneous 
mechanisms and clinical presentations. It can occur 
at doses significantly below the therapeutic range. 
Drug allergy should be differentiated from drug 
idiosyncrancy which is an abnormal and 
unexpected drug effect that is unrelated to its 
intended pharmacologic action, reproducible on re-
administration and is usually related to underlying 
abnormalities of metabolism, excretion or 
bioavailability.2 
Epidemiology: Giving an individual a label of 
drug allergy is common especially in children and 
often leads to lifelong avoidance of certain drugs 
particularly antibiotics. Allergic reactions are 
thought to account for less than 10% of all adverse 
drug reactions. However, the overall incidence of 
allergic drug reactions is difficult to estimate 
accurately due to the wide spectrum of disorders 
they encompass and a lack of accurate diagnostic 
tests. Additionally, most studies on incidence of 
allergic drug reactions include only adult subjects. 
There are limited epidemiological data for specific 
types of hypersensitivity disorders in pediatric 
patients. Diagnosis of drug allergy in children can 
be challenging because of the difficulty of 
undertaking intradermal or provocation tests. For 
this reason drug allergy is not usually confirmed by 
appropriate investigation and a pragmatic approach 
is often taken by avoiding the suspected drug. 3 
The overall incidence of adverse drug reactions 
in the general as well as pediatric populations is 
estimated to be 6.7%. Only 6-10% of adverse drug 
reactions can be attributed to an allergic or 
immunologic mechanism.4 The most common 
culprit drugs among new drug hypersensitivity 
reactions were antibiotics (32%), radio contrast 
media (26%) and anti-neoplastic drugs (17%). The 
estimated incidence of drug hypersensitivity 
reactions was 0.18 % among hospital admissions.5  
 
Risk factors for developing drug allergy 
The risk factors for the development of drug allergy 
are poorly understood and most of the limited data 
come from studies on penicillin allergy in adult 
subjects. The presence of atopy is not a risk factor 
for drug allergy,6 although patients with asthma 
may be more prone to having severe reactions (as is 
the case with food allergies).7,8 The parentral route 
of administration and repeated courses of the same 
or cross-reacting antibiotic appear to favor the 
development of immediate-type drug allergy.9 
Genetic susceptibility has been described for 
several types of drug allergy.10, 11 Patients with 
‘multiple drug allergy syndrome’ have an inherent 
predilection to develop hypersensitivity reactions to 
more than one non cross-reacting medication.12,13 
 
Pathogenesis and immunological classification of 
drug allergy 
Haptenation: Most medications, due to their 
relatively small size, are unable to elicit an immune 
response independently. Drugs must first covalently 
bind to larger carrier molecules such as tissue or 
serum proteins to act as complete multivalent 
antigens. This process is called haptenation and the 




may be humoral (with the production of specific 
antibodies), cellular (with the generation of specific 
T cells), or both. Most drugs are not reactive in 
their native state and must be converted (either 
enzymatically or via spontaneous degradation) to 
reactive intermediates in order to bind to proteins. 
Frequently, the identity of the intermediates is not 
known, making it impossible to develop accurate 
diagnostic tests for drug allergy. 14 
Pi-concept: The p-i concept (pharmacological 
interaction with immune receptors) is a recently 
described mechanism of drug allergy and it is an 
exception to the hapten hypothesis described above, 
since it requires neither haptenation nor formation 
of reactive intermediates. In this scheme, a drug 
binds noncovalently to a T cell receptor, which 
leads to an immune response via interaction with a 
major histocompatibility complex (MHC) receptor. 
No sensitization is required, since there is direct 
stimulation of memory and effector T cells, 
analogous to the concept of superantigens. It is not 
clear what proportion of allergic reactions to drugs, 
such as antibiotics, occur via the p-i mechanism vs 
the hapten mechanism.15 
Immunological classification of drug allergy: 
According to the Gell and Coombs system of 
hypersensitivity, drug allergy is comprised of 
immediate-type reactions mediated by drug-specific 
IgE antibodies (type I), cytotoxic reactions 
mediated by drug-specific IgG or IgM antibodies 
(type II), immune complex reactions (type III), and 
delayed-type hypersensitivity reactions mediated by 
cellular immune mechanisms (type IV).16 Type IV 
reactions can be subdivided into 4 categories 
involving activation and recruitment of monocytes 
(type IVa), eosinophils (type IVb), CD4+ or CD8+ 
T cells (type IVc), and neutrophils (type IVd) (table 
1).14 
 
Clinical manifestations of drug allergy 
Drug-induced allergic reactions can affect 
numerous organ systems and manifest in a variety 
of reactions, including various drug-induced 
allergic syndromes. Most of the cases present with 
cutaneous manifestations (about 70%) rather than 
systemic manifestations or anaphylaxis. 17
 
Table 1. Investigation of drug allergy/ hypersensitivity categorized by immunological mechanisms 17 




Urticaria, angio-oedema, anaphylaxis, 
bronchospasm 







IgG/M mediated cytotoxic 
reaction 
Anaemia, cytopenia, thrombocytopenia CBC/Coombs 
Test 
Type III 
IgG/M mediated immune 
complexes 
Vasculitis, lymphadenopathy, fever, 
arthropathy, rashes, serum sickness 





Th1 cells activate monocyte/ 
macrophages via IFN-γ and 
TNF-α 
Contact dermatitis, bullous exanthema Patch tests 
Type IVb 
Th2 cells drive eosinophilic 
inflammation via IL-5, IL-4, 
IL-13, eotaxin 
Maculopapular and bullous rashes, etc Patch tests 
Type IVc 
 
CD41/CD81 cytotoxic T cells 
kill targets via perforin, 
granzyme B, FasL 
Contact dermatitis, maculopapular,  
pustular and bullous exanthema.., etc. 
Patch tests 
Type IVd 
T cells recruit and activate 
neutrophils via CXCL-8, 
GM-CSF 
Pustular xanthemata Patch tests 
ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; LFT, liver function tests; U&E, urea and electrolytes; 
CXR, chest X-ray. IFN-γ: gamma interferon; TNF-α: Tumor necrosis factor alpha; IL: interleukin; CXCL-1: Chemokine (C-X-C 
motif) ligand 1; GM-CSF: granulocyte monocyte colony stimulating factor; CBC: Complete blood count; ANCA: Anti neutrophil 






Angio-oedema and acute systemic reactions 
Angio-oedema and acute systemic reactions can 
occur via IgE-mediated mechanism as in cases of 
penicillin, muscle relaxants, insulin and other 
hormones, while opiates, ACE-inhibitors, NSAIDs, 
radio-contrast media and plasma expanders produce 
angio-oedema or anaphylaxis by non-IgE-mediated 
mechanisms. Parentral administration is most likely 
to induce severe reactions including anaphylaxis. 18 
Penicillin has been reported as the cause in up to 
75% of fatal drug reactions.19 However, a survey of 
drug-induced anaphylaxis in the United Kingdom 




There are many clinical patterns of skin rash with 
different underlying immune mechanisms. Because 
certain drug eruptions are associated with specific 
immunologic reactions, it is important to 
characterize the type of eruption in order to be able 
to determine the possible cause, further diagnostic 
tests and management decisions. 21 
Type I IgE mediated reactions: Acute urticaria 
comprises erythematous wheals with individual 
lesions lasting 2–12 hours. Immunologically 
mediated urticaria resulting from type I IgE-
mediated mechanisms develop early if there has 
been previous exposure to the causal drug but less 
commonly 7–14 days after starting the first 
treatment course. Urticaria that is not IgE-mediated, 
e.g. to aspirin, NSAIDs, opiates, vancomycin or 




Figure 1. Acute Urticaria: Transient, well-
circumscribed, erythematous, annular papules on 
the trunk of a child few hours after the intake of an 
oral antibiotic (quoted from Kane et al, 2009)22 
 
 
Type IV T cell-mediated reactions: Clinically, 
type IV T cell-mediated reactions can be similar 
and most commonly result from exposure to 
antibiotics, anticonvulsants, anti-tuberculosis drugs, 
ACE inhibitors and NSAIDs. 23 So-called ‘toxic 
erythemas’ resemble urticarial wheals but are a 
form of T cell-mediated delayed hypersensitivity. 
Individual lesions last days rather than hours and 
develop 2–4 days after commencing the causative 
drug. Maculopapular rashes which also result from 
a T cell-mediated mechanism are symmetrical and 
may become confluent but spare the palms and the 
soles (figure 2).24 Delayed hypersensitivity 
responses may also be systemic, involving 
lymphoid organs and other tissues throughout the 
body. Sensitized T cells produce a wide array of 
proinflammatory cytokines that can ultimately lead 
to lymphocytic infiltrates, disseminated 
granulomata, and fibrosis. It has been suggested 
that there is a marked clinicopathological similarity 
between some late-onset drug reactions and graft 
versus host reactions that are initiated and 
maintained by T cells.25 
Allergic contact dermatitis after exposure to 
medications containing active drugs, additives, or 
lipid vehicles in ointments is the most frequent 
form of drug-mediated delayed hypersensitivity. 
Morphologically, it usually cannot be distinguished 
from contact irritant dermatitis. Almost any drug 
applied locally is a potential sensitizer, but fewer 
than 40 allergens produce most cases of contact 
dermatitis. Among the drugs involved, the most 
universally accepted offenders are topical 
formulations of bacitracin, neomycin, 
glucocorticosteroids, local anesthetics, and 
antihistamines. Potent excipient topical sensitizers 
include the parabens, formaldehyde, 
ethylenediamine, lanolin and thimerosal (figure 
3).26 
Additional T cell-mediated patterns include the 
‘fixed drug eruption’ (FDE) and ‘acute generalized 
exanthematous pustulosis’ (AGEP). In FDE red or 
brownish circular lesions develop at exactly the 
same site(s) following each exposure to the culprit 
drug. Sometimes these can be very extensive and 
can even blister, when they can be confused with 
SJS/TEN. However, there is generally absence of 
the systemic features and a much better prognosis. 
Common culprits include phenolphthalein-
containing laxatives, NSAIDs and antibiotics 
including sulphonamides. For unclear reasons, 
drug-specific memory T cells take up residence in 
the affected areas of skin (figure 4). In AGEP, an 
extensive rash of fine pustules arising on 
erythematous areas develops. Drug-specific T cells 
release large amounts of IL-8 which induces 




Figure 2. Toxic erythema: Acute morbilliform 
erythematous eruption that may occur due to drugs. 
Spontaneous resolution occurs over 1–2 weeks, 




Figure 3. Allergic contact dermatitis: Sharply 
demarcated linear erythematous plaque with early 
vesiculation on the abdomen of a child exposed to 
adhesive tape (quoted from Elston and Johnston, 
2007)27 
 
Erythema multiforme (EM), Stevens–Johnson 
syndrome (SJS) and toxic epidermal necrolysis 
(TEN): EM occurs as an eruption of circular, 
targetoid lesions spreading from the extremities to 
the face and trunk and involves the palms and soles. 
The initial lesions provoke a ‘burning’ feeling or 
pain but not itching. Lesions differ from urticaria 
and toxic erythemas in that the centres in EM are 
darker red. Bullous EM presents with target lesions 
and any blistering involves less than 10% of body 
surface area (BSA) (figure 6). SJS is characterized 
by widespread erythematous or purpuric lesions or 
flat atypical targets and blistering involving less 
than 10% of BSA in addition to mucous membranes 
involvement (figure 7). Overlap SJS/TEN presents 
with lesions that are like those in SJS but epidermal 
detachment affects between 10% and 30% of BSA. 
TEN may present with a rash which is like that in 
the overlap but epidermal detachment is more than 
30%; alternatively TEN may present without 
‘spots’ but with epidermal detachment in large 
sheets, affecting more than 30% BSA. The more 
severe syndromes can be life-threatening and the 
drug must be stopped immediately. 28 
Type II reactions: They include pemphigus and 
pemphigoid auto-immune blistering diseases in 
which specific autoantibodies target different 
antigenic constituents of the intercellular 
attachments in the epidermis (pemphigus) or the 
dermo-epidermal basement membrane 
(pemphigoid) (figure 8). 17 
Type III hypersensitivity reactions 
(hypersensitivity vasculitis): A purpuric/petechial 
rash may be indicative of a vasculitic process. 
Many agents, hematopoietic growth factors, 
cytokines and interferons are suspected of causing 
widespread vascular inflammation of skin and 
visceral organs. Frequently, the vascular changes 
occur during or at the endstage of drug-induced 
syndromes of serum sickness or drug fever. Drugs 
such as hydralazine, antithyroid medications, 
minocycline, and penicillamine are often associated 
with antinuclear cytoplasmic antibody or peri-
antinuclear cytoplasmic antibody– positive 
vasculitis-like disease. A Henoch-Schönlein 
purpura syndrome with cutaneous vasculitis and 
glomerulonephritis may be induced by 
carbidopa/levodopa. Further investigations 
including platelet count, renal function, C3/C4 
levels, ANA and skin biopsy may be required 
(figure 9).21 
In some cases, cutaneous reactions appear to result 
from drug administration in the presence of certain 
viral infections although the same drug may be 
subsequently tolerated. This suggests that for some 
drug reactions the presence of a systemic viral 
infection like Herpes viruses (Epstein–Barr) or HIV 
can act as a cofactor.29 
 
Respiratory reactions 
Airway involvement in drug-induced anaphylaxis 
may occur as a consequence of either laryngeal 
oedema causing upper airway obstruction or 
bronchial constriction or both. ACE-inhibitor-
induced angio-oedema is likely to result from 
reduced inactivation of bradykinin.30 Pulmonary 
eosinophilia is characterized by fever, rash, 
peripheral blood eosinophilia and pulmonary 
infiltrates visible on a chest radiograph as transient 
shadows. A number of drugs such as NSAIDs, 
penicillin, minocycline, nitrofurantoin and 
sulphasalazine may be responsible. Organizing 
pneumonia, alveolitis, pneumonitis, interstitial lung 






Figure 4. Fixed drug eruption: Hyperpigmented plaques of old lesions with superimposed 
erythema of new active lesions. Figure 5. Acute generalized exanthematous pustulosis: 
Numerous confluent pustules superimposed on the erythematous edematous confluent plaques 




Figure 6. Erythema multiforme Polycyclic target lesions with alternating rings of 
erythema and dusky desquamation on the arm. Figure 7.  Steven-Johnson syndrome: 
Debilitating mucosal involvement with hemorrhagic ulcerations and crusting requiring 
hospital admission (quoted from Kane et al, 2009)22. 
 
 
Figure 8. Bullous Pemphigoid: Itchy bullae that 
occur as autoimmune response to different 
antigens, mainly in the old age and tend to 
concentrate in flexural areas (quoted from Elston 
and Johnston, 2007)27 
 
Figure 9. Hypersensitivity Vasculitis over the 
leg after the intake of an oral NSAID (quoted 









Immune-mediated hepatocellular necrosis has been 
described with methyldopa, halothane, allopurinol, 
isoniazid and gold salts.32 Haemolytic anaemia can 
be caused by penicillin and methyldopa.17 The drug 
rash with eosinophilia and systemic symptoms 
(DRESS) syndrome is a drug-induced, multiorgan 
inflammatory response that can be life-threatening 
with symptoms of pyrexia, lymphadenopathy, 
hepatitis, nephritis, angio-oedema and eosinophilia. 
It was first described in conjunction with 
anticonvulsants, but later on, it was ascribed to a 
variety of other drugs like dapsone, minocycline, 
sulphasalazine, strontium ranelate and allopurinol. 
The reaction usually develops 2 to 8 weeks after 
therapy is started; symptoms can worsen after the 
drug is discontinued and symptoms can persist for 




History and examination 
History taking: A detailed history is an essential 
first step towards an accurate diagnosis of a drug-
induced reaction. The history helps guide the 
clinician in the choice of diagnostic tests and 
whether it might be safe to reintroduce the 
medication. The history must include details of the 
drug (formulation, dose, route and timing of 
administration) together with the nature and time of 
onset and resolution of symptoms.34 A thorough 
history is particularly important when patients are 
on several drugs. The diagnosis is aided by a 
detailed knowledge of the reaction-pattern for each 
drug taken. Medical notes, drug and nursing charts 
as well as photographs and eye-witness accounts 
should be sought in order to confirm the reaction 
and the implicated drug(s).17 
 A sample of clinically important questions 
that should be answered while evaluating a patient 
with suspected drug allergy include: Which systems 
(e.g., cutaneous, respiratory, and gastrointestinal) 
were involved in the reaction, and what were the 
characteristics? Was the patient taking concurrent 
medications at the time of the reaction? What was 
the therapeutic management required secondary to 
the reaction? Had the patient taken the same or a 
cross-reacting medication before the reaction? Has 
the patient experienced symptoms similar to the 
reaction in the absence of drug treatment? Does the 
patient have an underlying condition that favors 
reactions to certain medications? 21 
Clinical examination: In addition to the clinical 
history, a careful physical examination can help to 
define possible mechanisms underlying the reaction 
and guide investigations. Physical examination 
should include all systems that could possibly 
account for the clinical presentation. Cutaneous 
manifestations are the most common presentation 
for drug allergic reactions. Although drug allergic 
reactions may present with noncutaneous physical 
findings, these findings are generally nonspecific 
and are not nearly as helpful in diagnosis and 
management decisions as the cutaneous findings. 35 
Whether the rash is urticarial, maculopapular, 




Laboratory evaluation: Routine laboratory 
evaluation appropriate to the clinical setting might 
be useful for the evaluation of a patient with a 
suspected drug reaction, depending on the history 
and physical examination findings. Most patients 
with drug-induced allergic reactions do not have 
eosinophilia, and therefore the absence of 
eosinophilia clearly does not exclude a drug-
induced allergic cause. 21 Autoantibodies might be 
helpful in the evaluation of drug induced vasculitis 
(e.g., antinuclear cytoplasmic antibody) and drug-
induced lupus erythematosus (DILE). In the case of 
systemic DILE, antihistone antibody levels are 
frequently positive, whereas in patients with 
cutaneous DILE, anti-Ro/SSA, anti-La/ SSB, or 
both levels are frequently positive.36 
Diagnosis of anaphylaxis might be made by 
detecting an increase in serum total tryptase levels 
above baseline values or in serum mature tryptase 
(also known as b-tryptase) levels, which peak 0.5 to 
2 hours after drug administration and then decrease 
with a half-life of about 2 hours.37 Additional 
methods for detecting systemic mast cell mediator 
release include obtaining 24-hour urine collections 
for major urinary metabolites of histamine or 
prostaglandin D2.21 
Skin prick tests for specific Immunoglobulin E-
mediated drug reactions: Demonstration of the 
presence of drug-specific IgE is usually taken as 
sufficient evidence that the patient is at significant 
risk of having a type I reaction if the drug is 
administered. This is helpful in the case of high-
molecular-weight agents. In the case of small-
molecular-weight drugs, validated and reliable skin 
test reagents are only available for penicillin. The 
negative predictive value of penicillin skin testing 
(with penicilloyl polylysine, penicillin G, and 
penicilloate and/or penilloate) for serious 
immediate-type reactions approaches 100%. 
However, insufficient knowledge about drug 




they are conjugated with body proteins has been an 
impediment to developing either skin or in vitro 
assays for assessing immune responses to most 
other small molecular-weight drug chemicals.35 
 Skin prick tests for drug allergy are 
normally carried out at therapeutic concentrations 
unless the drug possesses intrinsic histamine-
releasing activity (e.g. atracurium and mivacurium) 
in which case a dilution of 10-3–10-1 may be 
appropriate to avoid false-positive results. The 
parentral preparation should be used for skin 
testing. If this is not available, an oral liquid may be 
used or a tablet dissolved for drugs that are soluble 
but only available in tablet form, although this is 
less likely to provide a reliable result.38 
Intradermal tests: Intradermal tests are more 
sensitive but less specific than SPTs if the same 
concentration is used. Intradermal testing requires 
considerable experience in both technique and 
interpretation. If the SPT is negative, intradermal 
tests are carried out by injecting 0.02–0.03 mL of 
the corresponding drug intradermally with a starting 
concentration of between 10-5 and 10-1 of that used 
for SPTs depending on the clinical situation. If the 
test is negative, 10-fold increasing concentrations 
are used sequentially until the test is positive or the 
highest non-irritant concentration is achieved.39 
Intradermal tests require expert interpretation to 
differentiate true positive from irritant reactions and 
to understand the significance of a negative test. 
Intradermal tests are more likely to trigger systemic 
allergic reactions and hence should only be 
undertaken after SPT and by experienced staff in a 
hospital setting with equipment available for 
resuscitation.40 
Patch tests for T cell sensitization: Patch testing 
involves placing potential allergens at non-irritant 
concentrations on the patient’s back for 48 hours 
under aluminum discs attached to hypoallergenic 
tape. Readings are performed at 48 and 96 hours. 
Experience is required to differentiate true 
hypersensitivity reactions from false-positive 
irritant reactions. False negatives occur due to poor 
skin penetration by large drug molecules or due to a 
low dose of drug used.41 A sensitivity range of 
between 11% and 43%, has been reported reflecting 
different populations selected for patch testing.42 
Drug patch testing might be useful for certain types 
of cutaneous drug reactions, including 
maculopapular exanthemas, acute generalized 
exanthematous pustulosis, and fixed drug eruptions, 
but generally is not helpful for SJS or urticarial 
eruptions.35 
Specific IgE in vitro assays (e.g. RASTs, 
ImmunoCAP, and Immulite): Specific IgE assays 
are available, although most are not adequately 
validated with unclear specificity and sensitivity 
and lack positive controls. In addition, in vitro 
assays for IgE to drugs are hampered because of 
difficulties with binding of drug allergens to solid-
phase matrices.21 Thus, although a positive in vitro 
test result for penicillin specific IgE can be highly 
predictive of penicillin allergy, a negative in vitro 
test result does not adequately exclude penicillin 
allergy.35 
Basophil activation test: The basophil activation 
test evaluates the expression of CD63 or CD203C 
on basophils after stimulation with an allergen. 
There are very limited data using this method to 
evaluate patients with possible drug allergies to b-
lactam antibiotics, NSAIDs, and muscle relaxants, 
and further confirmatory studies, especially with 
commercially available tests, are needed before its 
general acceptance as a diagnostic tool.43 
Skin biopsy: In complex cases in which multiple 
drugs are involved without a clear-cut temporal 
relationship, a skin biopsy might be useful. 
However, there are no absolute histologic criteria 
for the diagnosis of drug-induced eruptions and a 
skin biopsy might not definitively exclude 
alternative causes. 35 
 
Drug provocation tests: Challenge with specific 
drugs may be carried out after other possible 
investigations have been exhausted and the 
diagnosis remains in doubt. For each case a precise 
risk-benefit assessment must be established with the 
patient and referring clinician to determine whether 
the patient needs to be investigated. The primary 
aim of a provocation test is to exclude drug 
sensitivity but it can also be used to confirm a 
diagnosis. In the majority of cases, it is inadvisable 
to carry out provocation testing if the reaction has 
resulted in a life-threatening reaction. Even with 
less serious reaction, the rationale for provocation 
must be carefully considered and the challenge then 
only carried out by personnel experienced in drug 
challenges and with adequate resuscitation facilities 
readily available.44 Provocation tests are also 
performed for delayed reactions and it is then 
necessary to give a prolonged course of the 
suspected drug after an initial negative challenge in 
the clinic. Challenge testing is contraindicated for 
certain types of reactions, e.g. SJS, TEN, DRESS 
and EM and in patients with severe concurrent 
illness.17  
 A summary of drug provocation protocols 
has been reported in a retrospective study of 898 
consecutive patients. Written informed consent 
should be obtained before undertaking drug 
El-Owaidy 
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challenge. The starting dose for drug challenge will 
vary depending on the severity of the previous 
reaction, the dose that caused it and whether the 
challenge is oral or parentral.45 
 A negative reaction indicates that the 
patient is not sensitive at the time of the challenge.46 
However, false-negative reactions can occasionally 
occur due to missing co-factors such as viral 
infection or exercise, too low a dose being used for 
provocation, current or recent use of anti-allergic 
medications such as antihistamines, corticosteroids 
or anti-leukotrienes or conceivably due to 
desensitization by the challenge procedure. B-
blockers should be stopped 24 hours before the 
drug challenge.44 
 
Differential diagnosis of drug allergy 
Drug-induced allergic reactions can present in 
numerous ways, affecting single organs or with 
multiorgan involvement. However, each clinical 
presentation is not unique or specific to drug 
induced allergic reactions, and therefore other 
conditions might need to be considered based on 
the presentation (table 2). For example, a 
morbilliform eruption occurring in a child receiving 
amoxicillin for an upper respiratory tract infection 
might indeed be due to a viral exanthema and not a 
drug-induced allergic reaction. In addition, patients 
with multiple drug allergies might actually have an 
underlying chronic disease and are inappropriately 
labeled with multiple drug allergies. This frequently 
occurs in patients with underlying chronic urticaria 
or anxiety disorders but can also occur with other 
conditions, such as asthma, vocal cord dysfunction, 
idiopathic anaphylaxis or rarely even 
mastocytosis.21 
 
Management of drug allergy 
Acute drug reaction 
Anaphylaxis must be treated promptly and 
appropriately and steps should be taken to prevent a 
further reaction. Referral should be made to 
investigate the cause of the reaction. Safe 
alternative medication may need to be identified 
quickly in order to ensure continuity of patient care 
and in the acute stage this is often more important 
than confirming the identity of the offending drug. 
Cross reacting drugs should be identified and 
avoided. In less severe cases where there is no 
alternative to the suspected drug, suppression of 
symptoms using corticosteroids and/or 
antihistamines may be considered.17 Corticosteroids 
may also be required for immune complex 
reactions, drug-induced hematologic diseases, early 
stages of erythema multiforme major/ Stevens-
Johnson syndrome, and contact sensitivities.35 
 
Table 2. Conditions to consider in the differential 








DRESS, SJS, TEN): 
• Carcinoid syndrome • Acute graft-versus-
host disease 
• Insect bites/stings • Kawasaki disease 
• Mastocytosis • Still’s disease 
• Asthma • Psoriasis 
• Food allergy • Insect bites/stings 
• Scombroid fish poisoning • Viral infection 
• Latex allergy • Streptococcal 
infection 
•Infection (EBV, hepatitis A, 
B, C, gastrointestinal parasites) 
 
IgE: immunoglobulin E; EBV: Epstein-Barr virus; SJS: 
Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; 
DRESS: Drug rash with eosinophilia and systemic symptoms 
(quoted from Khan and Solensky, 2010)21 
 
Temporary induction of drug tolerance: 
Definition: Induction of drug tolerance procedures 
modifies a patient’s response to a drug to 
temporarily allow treatment with it safely. They are 
indicated only in situations where an alternate non–
cross-reacting medication cannot be used. Induction 
of drug tolerance can involve IgE immune 
mechanisms (desensitization), non-IgE immune 
mechanisms, pharmacologic mechanisms, and 
undefined mechanisms.35 This is rarely required but 
has been used for penicillin, certain other 
antibiotics, taxanes and platinum-based cancer 
chemotherapeutic agents.47 
Procedure: Induction of tolerance is started at a 
lower dose (10–1000 fold less) than that resulting in 
a positive intradermal reaction and increments 
given at regular intervals (every 20–30 min or every 
60–90 min orally) until the therapeutic dose is 
reached. The procedure may take between 6 hours 
to a few days depending on the starting dose, route 
of administration and challenge-induced symptoms 
requiring modification to the dosing-schedule. Oral 
route is less likely to provoke a severe reaction, but 
intravenous desensitization, e.g. for cephalosporins, 
may be necessary. The procedure must be 
performed in a hospital setting by experienced staff 
with full resuscitation equipment readily 
available.17 A number of penicillin desensitization 








Definition: Graded challenge, or test dosing, is 
defined as a procedure to determine whether a 
patient will have an adverse reaction to a particular 
drug by administering lower than therapeutic doses 
over a period of time with observation for reactions. 
The rationale for starting with a lower dose is based 
on the concept that a smaller dose of allergen will 
result in a less severe and more easily treated 
reaction.35 Unlike induction of drug tolerance 
procedures, a graded challenge does not modify a 
patient’s immunologic or nonimmunologic 
response to a given drug. Although it is not possible 
to be absolutely certain that a patient is not allergic 
to a drug because valid diagnostic tests are not 
available for most drugs, graded challenges are 
intended for patients who, after a full evaluation, 
are unlikely to be allergic to the given drug. 
Furthermore, the benefit of treatment with the drug 
should outweigh the risk of performing the graded 
challenge.21 
Procedure: The starting dose for graded challenge 
is generally higher than for induction of drug 
tolerance procedures, and the number of steps in the 
procedure might be 2 or several. The time intervals 
between doses are dependent on the type of 
previous reaction, and the entire procedure can take 
hours or days to complete. After a successful 
graded challenge and therapeutic course of the drug, 
future courses of the drug can be started without 
another challenge. A typical starting dose for a 
graded challenge is 1/100th of the final treatment 
dose. This is in contrast to the starting dose for an 
IgE immune induction of drug tolerance, in which 
case the starting dose is often 1/10,000th of the final 
dose. The choice of whether to introduce a 
clinically indicated drug through a graded challenge 
or through induction of drug tolerance mainly 
depends on the likelihood that the patient is allergic 
at the time of the procedure.35 
Contraindications: Graded challenge or induction 
of drug tolerance should almost never be performed 
if the reaction history is consistent with a severe 
non– IgE-mediated reaction, such as SJS, TEN, 
DRESS, hepatitis, or hemolytic anemia.2 
 
Prevention of future reactions 
This is an essential and often overlooked part of 
patient management. The patient should be given 
appropriate, written information about which drugs 
to avoid. The drugs should be highlighted in the 
hospital notes and within electronic records where 
available, and the GP informed. Engraved allergy-
bracelets are particularly useful when there is a risk 
of intravenous drug administration in an 
emergency, e.g. muscle relaxants, opiates or 
penicillin or when drugs, e.g. NSAIDs, are readily 
available without prescription. Adrenaline auto 
injectors are not usually required if the cause of the 
reaction has been identified and the drug is easily 
avoided.17  
 
In Summary, drug allergy is a common clinical 
problem; assessment by an allergist is important for 
appropriate diagnosis and management of the 
condition. Diagnosis relies on a careful history and 
physical examination and, in some instances; skin 
testing and graded challenges may be required. The 
mainstay of treatment for drug allergy is avoidance 
of the offending drug. When available, alternative 
medications with unrelated chemical structures 
should be substituted. If there is no suitable 
alternative, induction of drug tolerance procedures 
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